Introduction
============

Parkinson disease (PD) is a neurodegenerative movement disorder characterized by bradykinesia, rigidity, postural instability and tremor. PD prevalence increases with age, with estimates of 4--5% of the population being affected at 85 years and older (Fahn, [@b17]; Tansey et al., [@b54]). While the diagnosis of "idiopathic" PD is well established, there are many disorders that contain the essential elements of the PD phenotype, often termed Parkinsonism, such as progressive supranuclear palsy (PSP) and multiple system atrophy (MSA). Wider overlap also occurs, including frontotemporal dementia with Parkinsonism (FTDP-17) and Lewy Body Dementia (Wszolek et al., [@b62]). However, minimal clinical overlap has been reported between PD and amyotrophic lateral sclerosis (ALS), a neurodegenerative disorder characterized by progressive muscular paralysis reflecting degeneration of the motor neuron in the primary motor cortex, brainstem and spinal cord (Wijesekera and Leigh, [@b60]). Previous observations have linked Parkinsonism with motor neuron disease (Brait--Fahn disease) or the Guam PD-ALS-dementia complex. This raised the hypothesis that ALS and PD might be related, as members of a spectrum of phenotypes with shared pathophysiological elements (Brait et al., [@b3]; Uitti et al., [@b56]; Williams et al., [@b61]; Qureshi et al., [@b44]; Pinkhardt et al., [@b43]). However, consumption of the unusual amino acid BAA has subsequently been thought to be the cause of Guam PD-ALS-dementia, and the incidence of the disorder in Guam has dropped since dietary modifications (Khabazian et al., [@b26]; Pablo et al., [@b42]). Nonetheless, recently, a study has shown that rare genetic variants in the Angiogenin gene (*ANG*) contribute to the occurrence of both PD and ALS (van Es et al., [@b58]). Mutations in the Valosin Containing Protein gene (*VCP*) are linked with ALS and also have been postulated to be a risk factor for PD, though data reported to date are inconsistent (Johnson et al., [@b24]; Chan et al., [@b5]; Majounie et al., [@b35]). This raised the hypothesis that these two disorders share other common genes or pathways that contribute to the development of neurodegeneration. Therefore, when several reports recently demonstrated that large expansions of a hexanucleotide repeat in *C9ORF72* were correlated with the development of ALS (Renton et al., [@b47]; DeJesus-Hernandez et al., [@b10]; Gijselinck et al., [@b22]), we set out to examine the involvement of this complex repeat in PD. Interestingly, several subsequent publications (Boeve et al., [@b2]; Cooper-Knock et al., [@b7]; Mahoney et al., [@b32]; Simon-Sanchez et al., [@b53]) report an unexpected high presence of Parkinsonism and PD in ALS and FTD families of *C9ORF72* repeat expansion carriers. Here, we demonstrate that intermediate *C9ORF72* repeat copy numbers (\>20--30+ repeat copies) are observed at significantly higher levels in PD patients than controls.

Materials and Methods
=====================

Samples
-------

Initially, we evaluated 396 unrelated cases with PD (non-Hispanic/Latino Caucasians, range of age-at-onset (AAO): 10--85 year, average AAO: 53.6 year) and 12 cases of essential tremor with Parkinsonism (ETP) (Rocca et al., [@b48]). Patients were collected by 1 of 13 ascertainment centres in the PD Genetics Collaboration (Scott et al., [@b52]) or by the Morris K. Udall Parkinson Disease Center of Excellence (PI: Vance JM) ascertainment core. These participants were recruited primarily by participating movement disorder and neurology clinics. All individuals with PD and ET were examined by a board-certified neurologist. The diagnostic criteria used in evaluating ET patients are based on the Movement Disorders Society Consensus Criteria (Deuschl et al., [@b12]). Individuals are considered possibly affected with ET (types 1 and 2) when meeting criteria defined by the Tremor Investigation Group (Deuschl et al., [@b13]). Families with positive family history for FTD were excluded from the analysis. All patients were screened at ascertainment for cognitive status using the 3MS or short blessed test (Teng & Chui [@b55]; Katzman et al., [@b25]). Any cases with an onset of dementia within one year of the diagnosis of PD were excluded from the analysis. As positive controls for the hexanucleotide repeat, we included three ALS patients (M. Benatar, personal communication) with \>50 *C9ORF72* repeats (Renton et al., [@b47]). For the replication dataset, we used 481 patient DNA samples from the NINDS Human Genetics Resource Center DNA and Cell Line Repository (<http://ccr.coriell.org/ninds>). Clinical data for these patients are available online. The submitters that contributed samples are acknowledged in detailed descriptions of each panel: NDPT083-085-087-088-089-102-104-105. Of the 481 samples reported here, 169 samples were reported before by Majounie et al. ([@b33]). We selected samples for whom clinical data were provided by a neurologist (Caucasians, range of AAO: 7--87 year, average AAO: 55.3 year) to minimize the difference in inclusion criteria between the two patient groups in the initial and replication datasets. Both patient groups have similar percentages of early onset age (\<50 year; 39.5% versus 35%) and positive family history (36% versus 38%).

We evaluated 427 unaffected controls in the initial dataset (non-Hispanic/Latino Caucasians, range of age-at-exam (AAE): 60--101 year, average AAE: 77.2 year). In the replication analyses, an additional 717 controls (Caucasians, range of AAE: 60--100 year, average AAE: 71.7 year) were analysed. To lessen the chance of presymptomatic PD patients, we utilized controls older than 60 year that were collected for an ongoing study in Alzheimer disease (MPV PI). All controls scored within normal limits on the Modified Mini Mental State test and had normal neurological exams at age-of-exam. PD symptomology is an exclusion criterion for the controls in the Alzheimer disease study. The patients and controls have been included in GWAS before (Edwards et al., [@b15]) with no significant population stratification differences.

Genotyping: Repeat-Primed PCR and Haplotype SNP Genotyping
----------------------------------------------------------

The repeat-primed PCR assay used to screen for the (GGGGCC)~n~ repeat expansion limits the maximum number of repeats that can be detected to 60. The PCR cycling program of Renton et al. ( [@b47]) was modified to achieve more robust results on a Veriti 96-well Fast Thermal Cycler (Applied Biosystems, Life Technologies, Carlsbad, CA, USA). A custom PCR cycling program was used (4 min at 94°C; 50 cycles of 1 min at 94°C, 1 min at 64°C and 2 min at 72°C; 10 min at 72°C). Genotypes for the C9ORF72 risk haplotype SNPs (Mok et al., [@b37]) were available for this analysis from a previous GWAS study (Edwards et al., [@b15]) for 10 out of 14 intermediate repeat copy carriers. For the remaining four, the haplotype tag rs3849942 was genotyped by Sanger sequencing. Primer sequences flanking rs3849942 are F; 5′-GCAATTTCCTTGATTTGCAG and R; 5′-GGGGGAAAAGAGAAATGGAT. Fragment length analysis and Sanger sequencing were performed on an ABI 3730×l genetic analyser (Applied Biosystems, Life Technologies), and fragment analysis data were analysed using GeneMapper software (version 4.0, Applied Biosystems, Life Technologies).

Southern Blot
-------------

The 5 μg of DNA was digested with EcoRI and SacI. Digested samples were separated on a discontinuous 0.9% (4 cm)/1.5% (10 cm) agarose TAE gel, followed by partial depurination with HCl (0.4N) for 15 min and denaturation in NaOH (0.5N) for 30 min. DNA was transferred in 20× standard saline citrate (SSC) to a charged nylon membrane (Roche Applied Science, Indianapolis, USA) by capillarity. The 1 kb and 100 bp DNA ladders were used as size standards. The membranes were cross-linked and hybridized overnight at 47°C in roller bottles in Dig Easy Hybridization Buffer (Roche Applied Science) with a 241 bp probe synthesized by PCR from genomic DNA, using primers flanking exon 1 of C9ORF72 (5′-AGAACAGGACAAGTTGCC-3′ and 5′-AACACACACCTCCTAAACC-3′) labelled with Dig-11-dUTP by PCR (PCR Dig Synthesis Kit; Roche Applied Science). Filters were washed twice for 5 min in 2× SSC/1% SDS at room temperature and twice for 15 min in 1× SSC/0.1% SDS at 65°C. Filter blocking and signal detection were performed by incubating in blocking solution (DIG Nucleic Acid Detection Kit; Roche Applied Science) for 30 min, with the anti-DIG-AP antibody (1:5000 in blocking solution) for 30 min, and ultimately in the solution containing the NBT/BCIP substrate until the colour could be visualized. Images were captured with a Sony DSC-W350 digital camera and processed by Adobe Photoshop.

Statistical Methods
-------------------

To test whether higher repeat copy numbers increase one\'s risk for PD, we conducted Fisher\'s exact tests using the *a priori* thresholds of greater than 20 or 23 repeat copies (RCs). The common maximum RCs reported in controls in this study and others is 23 repeats, while by far the majority (∼99.4%) of all reported controls have RCs lower than 20 (DeJesus-Hernandez et al., [@b10]; Renton et al., [@b47]; Byrne et al., [@b4]; Cooper-Knock et al., [@b7]; Chio et al., [@b6]; Daoud et al., [@b9]; Dejesus-Hernandez et al., [@b11]; Dobson-Stone et al., [@b14]; Ferrari et al., [@b18]; Garcia-Redondo et al., [@b21]; Gijselinck et al., [@b22]; Konno et al., [@b28]; Majounie et al., [@b34]; Millecamps et al., [@b36]; Mok et al., [@b38]; Ogaki et al., [@b41]; Ratti et al., [@b45]; Rollinson et al., [@b49]; Rutherford et al., [@b50]; Sabatelli et al., [@b51]; Simon-Sanchez et al., [@b53]; van Rheenen et al., [@b59]; Xi et al., [@b63]; Yeh et al., [@b65]). Odds ratios represent the effect of intermediate repeat copies relative to lower repeat copies (≤20 or ≤23 RCs depending on analysis) and are calculated using a 2×2 contingency table. To test for overall distributional and mean differences, we used the Kolmogorov--Smirnov test and a standard *t*-test, respectively. Linear regression was used to test correlation between number of RCs and age-at-onset, age-at-exam or family history. To determine whether confounding influenced our pooling analysis, we applied the Cochran--Mantel--Haenszel test which performs pooled association analyses while controlling for datasets. All analyses were conducted using R software version 2.13.0. *p*-Values of 0.05 or below were considered statistically significant evidence of association.

Results
=======

Scoring of the PCR electropherogram found inconsistencies between different researchers when attempting to call one or two peaks. Thus, all samples with one or two peaks were merged into a single group. To determine the correlation of the number of peaks in the repeat-primed PCR assay with actual repeat copy number (RC), we sequenced the repeat region in 34 samples with variable peak numbers, using the unlabeled genotyping primers reported in DeJesus--Hernandez et al. ([@b10]). This demonstrated that the number of the actual RCs in our study equals the number of peaks plus 2.

The positive controls (ALS patients) had a maximum number of repeats greater than 50. The average maximum number of RCs in the initial clinical dataset was 6.9 in the controls and 8.2 in the cases (ranging ≤4 to ≥30) (Fig. [1](#fig01){ref-type="fig"}). There was no significant contribution of repeats \>30 in the PD cases. However, the PD cases had more intermediate size repeats (\>20 repeats to 30+) versus controls. As the majority of controls in the literature are reported to have less than 20 repeats, we used this value as a first *a priori* threshold for normal versus intermediate RCs (DeJesus-Hernandez et al., [@b10]; Renton et al., [@b47]; Millecamps et al., [@b36]; Sabatelli et al., [@b51]). We found eight PD patients, one ETP patient and one control with intermediate RCs (Table [1](#tbl1){ref-type="table"}) in our initial dataset. The one-tailed Fisher\'s exact test in the initial dataset showed significant association of the intermediate RCs with an increased risk for PD (*p* = 0.008; two-tailed *p* = 0.010). The odds ratio for the intermediate RCs in this original dataset is 9.6 \[95% CI: 1.32 -- 421\] (two-tailed). The confidence interval is very wide, likely due to the rarity of the intermediate repeat. Even when using the second, more stringent *a priori* threshold of 23 RCs---the common maximum number of repeats reported in controls---marginal significance was obtained (ratio patients:controls 4:0; one/two-tailed *p* = 0.05). The intermediate RC results in the clinical NINDS replication dataset are shown in Figure [2](#fig02){ref-type="fig"} and Table [2](#tbl2){ref-type="table"}. Patient ND09224 was reported before by Majounie et al. ([@b33]); differences in interpretation of the peak pattern might account for the variance in reported repeat copies. Again, the number of PD cases with intermediate repeats was twice that of controls, although the overall number of individuals with intermediate repeats was not large enough to reach significance (\>20 copies; ratio patients:controls 5:2, one-tailed *p* = 0.09, two-tailed *p* = 0.12; \>23 copies; ratio patients:controls 3:0, one/two-tailed *p* = 0.06). However, importantly, the pooled analysis of both clinical datasets (patients *N* = 889/controls *N* = 1144) (Fig. [3](#fig03){ref-type="fig"}) had more power and obtained a lower *p*-value than seen in either dataset: \>20RCs; patients:controls 14:3 (risk OR 6.1 \[95% CI: 1.68--33.1\] (two-tailed); one-tailed *p* = 0.001, two-tailed *p* = 0.002), \>23RCs; patients 7: controls 0 (one/two-tailed *p* = 0.003), indicating that the replication dataset strengthens the signal from the original dataset.

###### 

Clinical information of the patients in the initial dataset with 20 or more repeat copies

  Patient   \# of repeat copies   Gender   AAO   AAE   Family history   Phenotype                              Tremor    Bradykinesia   Rigidity     Gait disturbance   Dementia
  --------- --------------------- -------- ----- ----- ---------------- -------------------------------------- --------- -------------- ------------ ------------------ --------------
  P1        30                    F        20    97    Yes              Essential tremor with parkinsonism     Kinetic   Yes-(Mild)     Yes-(Mild)   No                 No
  P2        28                    M        31    34    No               Parkinson disease                      Resting   Yes            Yes          No                 Not assessed
  P3        25                    F        33    34    Yes              Parkinsonism with predominant tremor   Resting   No             No           Yes                No
  P4        24                    F        56    71    No               Parkinson disease                      Resting   Yes            Yes          Yes                No
  P5        23                    M        46    51    Yes              Parkinson disease                      Resting   Yes            Yes          Yes                Yes
  P6        22                    M        61    68    Yes              Parkinson disease                      Resting   Yes            No           Yes                No
  P7        21                    F        44    56    Yes              Parkinson disease                      Resting   No             Yes          Yes                No
  P8        21                    M        64    66    Yes              Parkinson disease                      Resting   Yes            No           Yes                Not assessed
  P9        21                    M        53    53    No               Parkinson disease                      Resting   Yes            Yes          Yes                No

AAO; age at onset, AAE; age-at-exam, Dementia; dementia at time of ascertainment.

###### 

Clinical information of the NINDS patients with 20 or more repeat copies

  Patient   \# of repeat copies   Gender   AAO   AAE   Family history   Phenotype           Tremor    Bradykinesia   Rigidity   Gait disturbance   Dementia
  --------- --------------------- -------- ----- ----- ---------------- ------------------- --------- -------------- ---------- ------------------ ----------
  ND00236   \>30                  M        40    60    yes              Parkinson disease   No        Yes            Yes        Yes                NA
  ND09224   26                    F        68    77    no               Parkinson disease   Resting   Yes            Yes        Yes                No
  ND02556   24                    M        65    77    no               Parkinson disease   Resting   Yes            Yes        Yes                NA
  ND03101   22                    F        61    74    no               Parkinson disease   Resting   Yes            Yes        Yes                NA
  ND00277   21                    M        40    65    no               Parkinson disease   Resting   Yes            Yes        Yes                NA

AAO; age at onset, AAE; age-at-exam, Dementia; dementia at time of ascertainment, Patient ND09224 was reported before by Majounie et al ([@b33]).
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Overall 2% of the 889 clinical PD cases had RCs \> 20. As the frequency of \>20RCs carriers in our control groups (∼0.3%) is lower than the overall frequency in the literature (∼0.6%), we performed the same association analysis in the total dataset adjusting for a higher frequency of \>20RCs as reported in controls. We still obtained evidence for significant association (\>20 copies; ratio patients:controls 14:'6', *p* = 0.015).

The 20 SNPs reported by Mok et al. ([@b37]) were genotyped in a previous GWAS for 10 out of 14 clinical intermediate repeat copy carriers (Edwards et al., [@b15]). All 10 intermediate copy carriers had the alleles of the risk haplotype (*N* = 20), with the exception of the most extreme ends of the haplotype in three individuals ([Table S1](#SD1){ref-type="supplementary-material"}). All intermediate copy carriers carried the T allele of SNP rs3849942, which "tags" the haplotype as the least frequent allele on the haplotype. Next, we examined this tagSNP in our full PD dataset. We found that 95% of the clinical cases and controls with greater than 8 repeats carried the tagging T allele versus 10% of those individuals with \<8 repeats (Fig. [4](#fig04){ref-type="fig"}). This led us to test whether there was an overall significant shift in the distribution of repeat size between cases and controls. In the initial clinical dataset, the distribution of the RCs was significantly different between cases and controls (KS test *p*-value = 5.28e-07, *t*-test for means of the distribution *p*-value = 6.68e-07). However, the NINDS dataset did not have a significant distribution shift of RCs in PD versus controls or a mean difference (KS test *p*-value = 0.97, *t*-test *p*-value = 0.98). A comparison of the two control groups showed that there were no differences in either the overall distribution or the repeat count mean that would account for this difference. While the NINDS set by itself was not significant, a combined analysis of both datasets showed a significant difference between overall distribution and distribution means of RCs between cases and controls (KS test *p*-value = 0.01/*t*-test *p*-value = 0.01), *p*-values being notably less significant than in the original analysis. As the histograms of both case groups showed differences in distribution (Figs [1](#fig01){ref-type="fig"} and [2](#fig02){ref-type="fig"}), we tested whether the results of the pooled analysis were due to confounding by the datasets. To control for having two different datasets, we performed the Cochran--Mantel--Haenszel test (CMH). The CMH test is analogous to a χ^2^ test, but can be used to control for differing datasets. The CMH results still showed significant results (*p* = 0.0064/*p* = 0.0074 for the two thresholds), indicating that results were not due to confounding.
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No evidence was seen for correlation of RCs with AAO (*p* = 0.792) for the clinical cases, or with AAE for the two clinical case and two control groups (*p* = 0.8246/*p* = 0.1624/*p* = 0.2513/*p* = 0.8284, respectively). No correlation of repeat length with dementia was observed in the patients of the initial dataset, for which data were available (*N* = 230) (*p* = 0.267). RC distributions of PD patients with early (\<40 year) versus late AAO and positive versus negative family history were not significantly different.

Genotype of \>20 Repeat Individuals Using Southern Blot
-------------------------------------------------------

We performed Southern blot analysis to determine whether the clinically affected individuals with \>20 RCs are heterozygous or homozygous carriers of two intermediate RC alleles, as the repeat-primed PCR for Patient 1 (P1) indicated two possible alleles with intermediate repeat copies (Fig. [5](#fig05){ref-type="fig"}B). All but two of the intermediate RC carriers of the original dataset were shown to be heterozygous for the intermediate allele and a low copy number allele (data not shown). The two other samples (P1; P9, Fig. [6](#fig06){ref-type="fig"}) were further analysed with additional control samples (see below). For Southern blot analysis of the NINDS intermediate samples, we obtained additional DNA from cultured cells. However, the DNA quality was insufficient to obtain a distinct band on Southern blot after multiple attempts.

![Segregation analysis in Family 1. (A) Pedigree. Symbols: Top right: ET type I; bottom right: possible ET type II; top left: ET by history; fully blackened: definite ET. (B) Electropherogram results of repeat-primed PCR of P1, aS and uS.](ahg0077-0351-f5){#fig05}
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One sample (P1; lane 4, Fig. [6](#fig06){ref-type="fig"}) was homozygous for intermediate repeats on Southern blot. Segregation analysis showed three different maximum intermediate RC alleles in her two offspring and herself (Fig. [5](#fig05){ref-type="fig"}). Southern blot analysis confirmed the repeat-primed PCR results and excluded the possibility of the other parent (no sample available) also being a carrier of an intermediate RC allele, as both sibs carry low copy alleles not originating from P1. This suggests that the allele with 26RC in the unaffected sib is derived from one of the alleles in patient P1, implying instability in the repeat. By her own history, P1 developed ET at the age of 20. For this study, the patient underwent a neurological exam when she was 97 year old. She presented with mild bradykinesia and rigidity, moderate postural and intention tremor in both upper extremities.

Thirteen of the intermediate patients with \>20 RCs had a phenotypic presentation that was compatible with classical PD (Tables [1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}). Eleven out of 14 patients have data available on levodopa response; all are responsive to L-dopa. A family history for ALS was not ascertained in these intermediate families. The intermediate RCs segregated genetically in a stable manner in several additional families. However, the intermediate alleles did not always segregate with PD ([Figs S1--S8](#SD2){ref-type="supplementary-material"}).

Discussion
==========

Renton et al. suggested pathogenic alleles for the *C9ORF72* repeat in ALS to be more than 30 RCs and benign alleles fewer than 20 RCs (Renton et al., [@b47]). Subsequent reports have identified rare controls in the 20 to 30RC range and more (DeJesus-Hernandez et al., [@b10]; Gijselinck et al., [@b22]; Simon-Sanchez et al., [@b53]), with the most commonly reported maximum RC number in controls as 23. We demonstrate here that intermediate expansions of the *C9ORF72* gene (\>20RCs) are associated with increased risk for clinically diagnosed PD. Moreover, combining two different clinical datasets, we found seven PD but no controls having over 23RCs. Six more reports have identified clinical PD patients with intermediate/expanded RCs (DeJesus-Hernandez et al., [@b11]; Majounie et al., [@b33]; Xi et al., [@b63]; Daoud et al., [@b8]; Harms et al., [@b23]; Lesage et al., [@b30]), with frequencies up to 2% amongst cases, similar to the work presented here. For five out of six reports, however, no risk assessment for the *C9ORF72* gene and PD relative to controls was performed. In the sixth study (DeJesus-Hernandez et al., [@b11]), a lack of association with increased PD risk was reported. However, in contrast to the other reports, no intermediate repeat copies above 23 were identified in the PD patients. For single allele analysis, they used cutoffs based on sample quintiles and percentiles, so no meaningful comparison can be evaluated with this report. However, it is interesting to note that the 95^th^ percentile (over 13 RCs) was the group with the highest increased odds ratio, though it was not significant.

We confirmed the presence of the tagging allele (T) of rs3849942 in 100% of all intermediate carriers and the full previously reported haplotype in all carriers where genotype data were available. In addition, the tagging allele was in 95% of all individuals with eight repeats or greater, versus 10% in individuals with less than 8 RC, which is consistent with a recent report by van der Zee et al. ([@b57]). These data indicate that genotyping this SNP could be used as a screening test to identify samples with possible higher repeat copy numbers. The reasons for this correlation are unknown, but it could be due to a specific haplotype background that contributes to the expansion. Alternatively, the initial expansion may have occurred only once on this background, leading to further expansion. Our previously reported GWAS (Edwards et al., [@b15]) showed no evidence for association with PD for rs3849942 (*p* = 0.852), indicating that the effect we report here is specific to the repeat, not the underlying haplotype.

Interestingly, several studies have suggested an excess of clinical PD or Parkinsonism cases in *C9ORF72* repeat expansion families (Boeve et al., [@b2]; Cooper-Knock et al., [@b7]; Mahoney et al., [@b32]; Simon-Sanchez et al., [@b53]). This finding could be explained if, indeed, the intermediate allele described here is a "premutation" allele for ALS. The clinical phenotype of the majority of the patients with greater than 20 RCs appears to be consistent with "typical" PD with no clinical evidence of motor neuron disease. Furthermore, we saw no evidence for ALS in our family histories. As ALS is much less frequent than PD, if such a relationship existed, it is more likely to be observed in the rarer ALS families than *vice versa*. The PD patients with ≥30 RCs did not have symptoms observed (Udall patient) or reported (NINDS patient) indicative of ALS or FTD. Two other reports of intermediate/expanded repeats in clinical PD cases, however, indicate that some of these carriers present with a family history of atypical Parkinsonism or other neurodegenerative disorders (AD, ALS) (Xi et al., [@b63]; Lesage et al., [@b30]).

The lack of segregation of the intermediate RC allele with clinical PD in the small number of families studied here (with asymptomatic carriers at an age that exceeds the AAO of their affected relative) and the occurrence of intermediate/expanded repeats in some controls suggests that it is most likely a susceptibility risk factor, rather than causal for PD/Parkinsonism.

Although the research to elucidate the disease mechanism of this intermediate/expanded repeat is still in its infancy, the first reports suggested binding of the repeat to other RNAs, sequestering both from normal processing (Renton et al., [@b47]), inclusion of the repeat in nuclear foci, also supporting RNA binding as a possible mechanism, and reduced protein expression and affected splicing (DeJesus-Hernandez et al., [@b10]). Subsequent functional studies report on the presence of di-peptides---translated from the repeat in the mRNA through repeat associated non-ATG (RAN) translation---in the pathology of large, expanded repeat carriers (Ash et al., [@b1]; Mori et al., [@b39]). This RAN translation is possible due to formation of stable secondary structures, hairpins or G-quadruplex structures, by the repeat in the mRNA (Fratta et al., [@b19]; Reddy et al., [@b46]). Additionally, analyses of the effect of the repeat in cell and *Drosophila* models indicated that repeat expression (30 RCs used in the report) is sufficient to cause neurodegeneration (Xu et al., [@b64]). The authors identified one RNA-binding protein (Pur α) binding to the repeat in a concentration-dependent manner. Overexpression of Pur α seemed to rescue the phenotype caused by the repeat, supporting the hypothesis of RNA sequestration as a possible disease mechanism. It has been shown that multiple other genes contributing to ALS risk (*FUS, TDP43, ANG*) are involved in RNA metabolism as well (Emara et al., [@b16]; Lagier-Tourenne et al., [@b29]).

The finding of an abnormally expanded number of repeats in PD, but fewer than that observed in ALS, is reminiscent of Fragile X-associated Tremor/Ataxia Syndrome (FXTAS)/Fragile X (Garcia-Arocena & Hagerman [@b20]) and ATXN2 (*SCA2*) (Kim et al., [@b27]). In these disorders, intermediate RCs (premutations) are associated with Parkinsonism. The mechanism proposed for FXTAS is that the repeat, also G-C rich, binds local RNA, creating local cell stress and damage. Interestingly, *ATXN2* has also been reported to be involved in RNA metabolism (Nonhoff et al., [@b40]), so this is another area of common overlap.

Finally, initial evidence suggested that the repeat may become unstable with increasing numbers (Renton et al., [@b47]). We did observe instability of the repeat in blood between patient 1 and her offspring with a loss of repeat copies. Repeats of intermediate length are reported to be prone to both gaining and losing copies as opposed to longer repeats whose length mostly increases (Li et al., [@b31]). The instability of the intermediate repeats might allow them to reach a threshold where further elongation to pathogenic lengths is more likely.

In summary, these data suggest that not only do the *C9ORF72* repeats contribute to significant risk of developing PD/Parkinsonism, but that abnormal RNA metabolism may also be an important pathogenesis factor in PD as well, and should be further investigated.
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**Table S1** Analysis of 20 SNP risk haplotype in *C9ORF72* intermediate repeat carriers.

**Figure S1** Segregation analysis in Family 2.

**Figure S2** Segregation analysis in Family 3.

**Figure S3** Segregation analysis in Family 4.

**Figure S4** Segregation analysis in Family 5.

**Figure S5** Segregation analysis in Family 6.

**Figure S6** Segregation analysis in Family 7.

**Figure S7** Segregation analysis in Family 8.

**Figure S8** Segregation analysis in Family 9.
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